Professor | Yueyin Pan | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yueyin Pan
Contact Information	yueyinpan1965@126.com
Language ability	Chinese, English
Province	Anhui

Upload Avatar (500 x 500)

Name

Yueyin Pan

Contact Information

yueyinpan1965@126.com

Language ability

Chinese, English

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	2003.09–2007.07 PhD in Clinical Pharmacology: Anhui Medical University 1997.09–2000.07 Master's in Public Health: Anhui Medical University 1982.09–1987.07 Bachelor's: Wannan Medical College State Council Special Allowance Expert Jianghuai Famous Doctor
Work Experience	2016.07-present - University of Science and Technology of China First Affiliated Hospital West District - Vice President 2007.12-2016.07 - Anhui Medical University First Affiliated Hospital - Chief Physician in Oncology 2007.11-2008.10 - Harvard Medical School, BWH/DANA-FARBER - Visiting Scholar 1987.09-2007.12 - Anhui Medical University First Affiliated Hospital - Resident Physician, Attending Physician, Associate Chief Physician
Awards	Anhui Science and Technology Award (2021): First Prize

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

2003.09–2007.07 PhD in Clinical Pharmacology: Anhui Medical University
1997.09–2000.07 Master's in Public Health: Anhui Medical University
1982.09–1987.07 Bachelor's: Wannan Medical College
State Council Special Allowance Expert
Jianghuai Famous Doctor

Work Experience

2016.07-present - University of Science and Technology of China First Affiliated Hospital West District - Vice President
2007.12-2016.07 - Anhui Medical University First Affiliated Hospital - Chief Physician in Oncology
2007.11-2008.10 - Harvard Medical School, BWH/DANA-FARBER - Visiting Scholar
1987.09-2007.12 - Anhui Medical University First Affiliated Hospital - Resident Physician, Attending Physician, Associate Chief Physician

Awards

Anhui Science and Technology Award (2021): First Prize

Areas of Focus	Research on the efficacy prediction and resistance mechanisms of anti-tumor drugs
Publications	Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping, Jin W, Shan B, Liu H, Zhou S, Li W, Pan J, Lin L, Hu D, Pan Y, 2019 Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath, Shan B, Broza YY, Li W, Wang Y, Wu S, Liu Z, Wang J, Gui S, Wang L, Zhang Z, Liu W, Zhou S, Jin W, Zhang Q, Hu D, Lin L, Zhang Q, Li W, Wang J, Liu H, Pan Y, Haick H, 2020 Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity, Huang Y#, Wang H, Hao Y, Lin H, Dong M, Ye J, Song L, Wang Y, Li Q, Shan B, Jiang Y, Li H, Shao Z, Kroemer G, Zhang H, Bai L, Jin T, Wang C, Ma Y, Cai Y, Ding C, Liu S, Pan Y, Jiang W, Zhou R, 2020 Glutathione and Reactive Oxygen Species Dual-Responsive Block Copolymer Prodrugs for Boosting Tumor Site-Specific Drug Release and Enhanced Antitumor Efficacy, Yin W#, Ke W, Lu N, Wang Y, Japir AAMM, Mohammed F, Wang Y, Pan Y, Ge Z, 2020 An artificial neural network model based on DNA damage response genes to predict outcomes of lower-grade glioma patients, Chen J, QianX, He Y, Han X, Pan Y, 2021 Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study, Jie Zhang#, Yueyin Pan#, Qin Shi#, Guojun Zhang#, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, Aimin Zang, Qisen Guo, Guangqiang Zhao, Ziping Wang, Jianxing He, Wenxiu Yao, Xiaohong Wu, Kai Chen, Xiaohua Hu, Chunhong Hu, Lu Yue, Da Jiang, Guangfa Wang, Junfeng Liu, Guohua Yu, Junling Li, Jianling Bai, Wenmin Xie, Weihong Zhao, Lihong Wu, Caicun Zhou, 2022 Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study, Yao Y, Wang Y, Du Y, Jiang F, Liang H, Bi M, Xie H, Peng W, Pan Y, 2023

Areas of Focus

Research on the efficacy prediction and resistance mechanisms of anti-tumor drugs

Publications

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping, Jin W, Shan B, Liu H, Zhou S, Li W, Pan J, Lin L, Hu D, Pan Y*, 2019
Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath, Shan B, Broza YY, Li W, Wang Y, Wu S, Liu Z, Wang J, Gui S, Wang L, Zhang Z, Liu W, Zhou S, Jin W, Zhang Q, Hu D, Lin L, Zhang Q, Li W, Wang J, Liu H, Pan Y*, Haick H*, 2020
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity, Huang Y#, Wang H, Hao Y, Lin H, Dong M, Ye J, Song L, Wang Y, Li Q, Shan B, Jiang Y, Li H, Shao Z, Kroemer G, Zhang H, Bai L, Jin T, Wang C, Ma Y, Cai Y, Ding C, Liu S*, Pan Y*, Jiang W*, Zhou R*, 2020
Glutathione and Reactive Oxygen Species Dual-Responsive Block Copolymer Prodrugs for Boosting Tumor Site-Specific Drug Release and Enhanced Antitumor Efficacy, Yin W#, Ke W, Lu N, Wang Y, Japir AAMM, Mohammed F, Wang Y, Pan Y*, Ge Z*, 2020
An artificial neural network model based on DNA damage response genes to predict outcomes of lower-grade glioma patients, Chen J, QianX, He Y, Han X, Pan Y*, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study, Jie Zhang#, Yueyin Pan#, Qin Shi#, Guojun Zhang#, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, Aimin Zang, Qisen Guo, Guangqiang Zhao, Ziping Wang, Jianxing He, Wenxiu Yao, Xiaohong Wu, Kai Chen, Xiaohua Hu, Chunhong Hu, Lu Yue, Da Jiang, Guangfa Wang, Junfeng Liu, Guohua Yu, Junling Li, Jianling Bai, Wenmin Xie, Weihong Zhao, Lihong Wu, Caicun Zhou, 2022
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study, Yao Y, Wang Y, Du Y, Jiang F, Liang H, Bi M, Xie H, Peng W, Pan Y, 2023

Anti-Tumor Drugs Efficacy Prediction Resistance Mechanisms Cancer Treatment Drug Development Oncology Pharmacology Clinical Research Biomarkers Personalized Medicine

Wei Wei - University of Science and Technology of China

Chao Xu - University of Science and Technology of China

Qing Ye - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us